Evidence check: CYP1A2 in the context of gut health

CYP1A2 is a key phase I metabolic enzyme primarily known for metabolizing caffeine and various drugs. A direct, evidence-based link between CYP1A2 variants and gut health is not established in the provided context. While mechanistic hypotheses suggest that CYP1A2 could influence gut barrier function or the microbiome via xenobiotic metabolism, robust human studies are lacking. MyBody-X tests typically include CYP1A2 for caffeine metabolism insights, not specifically for gut health. Thus, any gut-related claims are speculative. If combined with microbiome or blood biomarkers, indirect associations might emerge, but a single SNP analysis is insufficient. Be cautious of marketing overreach: the evidence grade is unclear. For a reliable gut health assessment, clinical evaluation, dietary logs, and stool tests are far more informative than a single genetic variant.